Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line chemotherapy factorial trial in mucinous epithelial ovarian cancer
ISRCTN83438782Phase 3Completed
- Sponsor
- University College London
- Start
- Jan 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carboplatin, paclitaxel, oxaliplatin, capecitabine and bevacizumab in mucinous ovarian cancer (MOC) and fallopian tube cancer (PFTC), sponsored by University College London. Started Jan 2010; status: completed.
02
Drugs
carboplatinpaclitaxeloxaliplatincapecitabinebevacizumab
03
Conditions
mucinous ovarian cancer (MOC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ISRCTN83438782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83438782.